The pulsatile gonadorelin pump induces earlier spermatogenesis than cyclical gonadotropin therapy in congenital hypogonadotropic hypogonadism men
A bomba pulsátil de gonadorelina induz espermatogênese mais precocemente que a terapia cíclica com gonadotrofinas em homens com hipogonadismo hipogonadotrófico congênito
Zhang L, Cai K, Wang Y, Ji W, Cheng Z, Chen G, Liao Z
Am J Mens Health
Summary
This comparative study evaluated the efficacy of a pulsatile gonadorelin pump versus cyclical gonadotropin therapy (hCG + FSH) for inducing spermatogenesis in 28 men with congenital hypogonadotropic hypogonadism (CHH). Patients were divided into two groups: pulsatile GnRH pump treatment (subcutaneous gonadorelin pulses every 90 minutes) or combined intramuscular hCG and FSH therapy in cycles.
The results demonstrated significant superiority of the pulsatile gonadorelin pump:
- Median time to sperm appearance: 6 months with pulsatile pump versus 14 months with cyclical gonadotropins
- Spermatogenesis induction success rate: significantly higher in the pump group
- Testicular volume: faster and more pronounced increase with the pulsatile pump
The advantage of the pulsatile pump lies in its ability to mimic the physiological pattern of GnRH secretion from the hypothalamus, stimulating the pituitary to produce LH and FSH in a coordinated, pulsatile manner. This "top-down" approach preserves endocrine feedback mechanisms, while exogenous gonadotropin therapy bypasses pituitary regulation.
The authors concluded that the pulsatile gonadorelin pump should be considered as first-line treatment for fertility induction in men with CHH, especially when timing is a relevant factor. These data reinforce the importance of pulsatility in male reproductive physiology and the superiority of approaches that respect normal endocrine physiology.
Related Peptide
Gonadorelin
GnRH
Gonadotropin-releasing hormone (GnRH). Stimulates LH and FSH release from the pituitary gland. Research on the HPG axis. Pulsatile administration may be beneficial.